Text this: Asciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator‐Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study
